title: Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.
authors.affiliation: Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
authors.forename: Imke
authors.initials: I
authors.lastname: Satzger
authors.forename: Annette
authors.initials: A
authors.lastname: Degen
authors.forename: Hiba
authors.initials: H
authors.lastname: Asper
authors.forename: Alexander
authors.initials: A
authors.lastname: Kapp
authors.forename: Axel
authors.initials: A
authors.lastname: Hauschild
authors.forename: Ralf
authors.initials: R
authors.lastname: Gutzmer
mesh_terms: D000368:Aged; D059248:Chemoradiotherapy / Q000009:adverse effects; D003877:Dermatitis, Contact / Q000209:etiology*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008875:Middle Aged; D010091:Oximes / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D011832:Radiation Injuries / Q000139:chemically induced / Q000209:etiology*; D020266:Radiotherapy, Conformal / Q000009:adverse effects; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib